Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1111/eci.13436
Twittear
Título: | Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19 |
Fecha de publicación: | 2020 |
Editorial: | Wiley |
Cita bibliográfica: | European Journal of Clinical Investigation 2021;51:e13436. |
ISSN: | Print: 0014-2972 Electronic: 1365-2362 |
Materias relacionadas: | CDU::6 - Ciencias aplicadas::61 - Medicina |
Palabras clave: | Anticoagulantes Fibrilación auricular COVID-19 SARS-CoV-2 Trombosis Tromboembolismo venoso Anticoagulant Atrial fibrillation Coronavirus disease 2019 SARS-CoV-2 Thrombosis, |
Resumen: | Background: The coronavirus disease 2019 (COVID-19) shows high morbidity and mortality, particularly in patients with concomitant cardiovascular diseases. Some of these patients are under oral anticoagulation (OAC) at admission, but to date, there are no data on the clinical profile, prognosis and risk factors of such patients during hospitalization for COVID-19. Design: Subanalysis of the international ‘real-world’ HOPE COVID-19 registry. All patients with prior OAC at hospital admission for COVID-19 were suitable for the study. All-cause mortality was the primary endpoint. Results: From 1002 patients included, 110 (60.9% male, median age of 81.5 [IQR 75-87] years, median Short-Form Charlson Comorbidity Index [CCI] of 1 [IQR 1-3]) were on OAC at admission, mainly for atrial fibrillation and venous thromboembolism. After propensity score matching, 67.9% of these patients died during hospitalization, which translated into a significantly higher mortality risk compared to patients without prior OAC (HR 1.53, 95% CI 1.08-2.16). After multivariate Cox regression analysis, respiratory insufficiency during hospitalization (HR 6.02, 95% CI 2.18-16.62), systemic inflammatory response syndrome (SIRS) during hospitalization (HR 2.29, 95% CI 1.34-3.91) and the Short-Form CCI (HR 1.24, 95% CI 1.03-1.49) were the main risk factors for mortality in patients on prior OAC. Conclusions: Compared to patients without prior OAC, COVID-19 patients on OAC therapy at hospital admission showed lower survival and higher mortality risk. In these patients on OAC therapy, the prevalence of several comorbidities is high. Respiratory insufficiency and SIRS during hospitalization, as well as higher comorbidity, pointed out those anticoagulated patients with increased mortality risk. |
Autor/es principal/es: | Rivera-Caravaca, José Miguel Núñez-Gil, Iván J. Vivas, David Viana-Llamas, María C. Uribarri, Aitor Becerra-Muñoz, Víctor Manuel Trabattoni, Daniela Fernández Rozas, Inmaculada Feltes, Gisela López-Pais, Javier El-Battrawy, Ibrahim Macaya, Carlos Fernández-Ortiz, Antonio Estrada, Vicente Marín Ortuño, Francisco |
Facultad/Departamentos/Servicios: | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Enfermería |
URI: | http://hdl.handle.net/10201/138843 |
DOI: | https://doi.org/10.1111/eci.13436 |
Tipo de documento: | info:eu-repo/semantics/article |
Número páginas / Extensión: | 11 |
Derechos: | info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Descripción: | ©<2020>. This manuscript version is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the, Accepted, version of a Published Work that appeared in final form in European Journal of Clinical Investigation. To access the final edited and published work see: https://doi.org/10.1111/eci.13436 |
Aparece en las colecciones: | Artículos: Enfermería |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Clinical profile and prognosis in patients on oral anticoagulation.pdf | 221,55 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons